MIST — Milestone Pharmaceuticals Inc
NASDAQ · Healthcare · Biotechnology
$1.14
-$0.02 (-1.72%)
Milestone Pharmaceuticals Inc (MIST) is a biotechnology company listed on NASDAQ. It is led by Joseph G. Oliveto M.B.A., based in 1111 Dr. Frederik-Philips Boulevard, Montreal, QC, Canada, H4M 2X6, with about 38 employees. Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. It offers CARDAMYST (etripamil) nasal spray, a prescription medication for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. The company is also developing etripamil for the indication of atrial fibrillation with rapid ventricular rate (AFib-RVR). It has a license and collaboration agreement with Corxel Pharmaceuticals to develop and commercialize etripamil. Milestone Pharmaceuticals Inc.was incorporated in 2003 and is headquartered in Montreal, Canada.
Net income was -$45.6M. MIST currently screens at market cap $160.6M.
Use this MIST page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the MIST quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the MIST SEC filings page. Lician reads the product cache first so this HTML stays unique to Milestone Pharmaceuticals Inc even when a live quote feed is slow.
About Milestone Pharmaceuticals Inc
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. It offers CARDAMYST (etripamil) nasal spray, a prescription medication for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. The company is also developing etripamil for the indication of atrial fibrillation with rapid ventricular rate (AFib-RVR). It has a license and collaboration agreement with Corxel Pharmaceuticals to develop and commercialize etripamil. Milestone Pharmaceuticals Inc.was incorporated in 2003 and is headquartered in Montreal, Canada.
MIST Key Statistics
Market Cap
$160.60M
Volume
886,949
Previous Close
$1.04
Day Range
$1.04 – $1.15
EPS
-$0.67
Revenue
$0.00
Net Income
-$41.52M
Gross Profit
$0.00
Free Cash Flow
$0.00
Employees
38
MIST Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$41.52M | -$59.69M | -$58.39M | -$42.85M |
| EPS (Diluted) | -$0.67 | -$1.39 | -$1.38 | -$1.02 |
Total Assets
$75.50M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$25.31M
Operating Cash Flow
-$28.85M
Free Cash Flow
$0.00
Milestone Pharmaceuticals Inc Company Information
- CEO, President & Executive Director
- Joseph G. Oliveto M.B.A.
- Headquarters
- 1111 Dr. Frederik-Philips Boulevard, Montreal, QC, Canada, H4M 2X6
- Website
- www.milestonepharma.com
- Phone
- 514 336 0444
- IPO / Founded
- 2019-05-09
- Sector
- Healthcare
- Industry
- Biotechnology